Recent Updates
Recently added Catalysts

Durogesic

Phase 3

Chronic Pain | Small molecule | Pain |Johnson & Johnson|Last Updated: May 18, 2011

Target and mechanism

ModalitySmall molecule

Also known as Durogesic® (fentanyl transdermal drug delivery system)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment41

FDA Designations

No designations recorded

Clinical trial landscape

Durogesic · 1 trial · 1 indication

Phase 3 1
NCT00271453A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief TherapyChronic Pain
COMPLETED41 Analytics
PHASE3COMPLETED
A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy
Chronic Pain
NCT0027145341
Unlock trial analytics

Study Endpoints

Primary Endpoints

Patient assessment of treatment at Day 15; Pain level assessed once in the morning and in the evening; Amount of rescue medication that the patient requires; Pain level at the time rescue medication is given and one hour afterwards

Secondary Endpoints

Investigator and parent global assessment of the patient's treatment with respect to pain control, side effects and convenience; Pharmacokinetics; Incidence of adverse events
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Durogesic® (fentanyl transdermal drug delivery system)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range2 Years to 18 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients with a confirmed malignancy (whose pain is judged by the investigator to be caused by the malignancy), or patients with other life-threatening/terminal disease whose pain requires treatment with strong opioid analgesia * requiring treatment of pain with a strong opioi...

Unlock Eligibility Criteria

Competitive Landscape -Chronic Pain 49 trials

CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY2PHASE3Retatrutide
Boston Scientific CorporationBSX5N/AUndisclosed
Creative Medical Technology Holdings, Inc.CELZ1PHASE1CELZ-201-DDT
Zimmer Biomet Holdings, Inc.ZBH6N/AUndisclosed
Hinge Health, Inc. Class AHNGE2N/AUndisclosed
Abbott LaboratoriesABT2N/AUndisclosed
SI-BONE, Inc.SIBN1 - Undisclosed
Axogen, Inc.AXGN1N/AUndisclosed
United Therapeutics CorporationUTHR1PHASE1Metformin
Precision BioSciences, Inc.DTIL1PHASE1MC-1-50
Galapagos NV Sponsored ADRGLPG1 - Undisclosed
Medtronic PlcMDT1 - Undisclosed
Forte Biosciences Inc.FBRX2N/AUndisclosed
Teleflex IncorporatedTFX1 - Undisclosed
Collegium Pharmaceutical, Inc.COLL1N/AUndisclosed
Sage BionetworksSAGE1 - Undisclosed
Unlock Competitive Intelligence